Home » Stocks » ABMD

Abiomed, Inc. (ABMD)

Stock Price: $318.97 USD -4.82 (-1.49%)
Updated Feb 25, 2021 1:36 PM EST - Market open
Market Cap 14.55B
Revenue (ttm) 812.94M
Net Income (ttm) 200.47M
Shares Out 45.20M
EPS (ttm) 4.39
PE Ratio 72.71
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $318.97
Previous Close $323.78
Change ($) -4.82
Change (%) -1.49%
Day's Open 324.02
Day's Range 317.76 - 326.93
Day's Volume 96,902
52-Week Range 119.01 - 387.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GuruFocus - 45 minutes ago

Investors searching for value opportunities may want to have a look at the three stocks listed below, as they represent equities in companies with high profitability and robust financial condi...

Other stocks mentioned: DECK, GGG
Business Wire - 1 week ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the appointment of Myron Rolle, MD, to the Abiomed Board of Directors.

Business Wire - 1 week ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at upcoming investor conferences.

Kiplinger - 1 week ago

The market itself is sitting at lofty valuations, but several S&P 500 stocks are extremely overheated. Consider giving these 10 picks a little time to cool off.

Other stocks mentioned: CMG, FTNT, ILMN, MSCI, RMD, ROL, TER, UA, UAA, ZBRA
Zacks Investment Research - 2 weeks ago

Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.

The Motley Fool - 3 weeks ago

It's not a vaccine company, a drugmaker, or a diagnostics company.

Zacks Investment Research - 3 weeks ago

The study proves that Abiomed's (ABMD) Impella 5.5 with SmartAssist delivers successful clinical and device outcomes.

Business Wire - 3 weeks ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces a large study of 356 patients treated with Impella 5.5 with SmartAssist at 16 U.S. and German centers found a 79% survival rat...

The Motley Fool - 3 weeks ago

The company released its latest quarterly report.

Seeking Alpha - 4 weeks ago

Abiomed, Inc.'s (ABMD) CEO Michael Minogue on Q3 2021 Results - Earnings Call Transcript

Zacks Investment Research - 4 weeks ago

ABIOMED's (ABMD) international Impella revenues improve in Q3.

Zacks Investment Research - 4 weeks ago

Abiomed (ABMD) delivered earnings and revenue surprises of 1.74% and 2.81%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 4 weeks ago

Shares of Abiomed (NASDAQ:ABMD) were unchanged after the company reported Q3 results. Quarterly Results Earnings per share rose 20.54% year over year to $1.35, which beat the estimate of $1.13.

Business Wire - 4 weeks ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q3 fiscal year 2021 record revenue of $232 million, up 5% year over year with 31% operating margin.

Zacks Investment Research - 4 weeks ago

The strong momentum of ABIOMED's (ABMD) Impella product line, both in Europe and Japan, is expected to have continued in the fiscal third quarter as well.

Business Wire - 1 month ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the company will release financial results for the third quarter of fiscal 2021 on January 28, 2021.

Zacks Investment Research - 1 month ago

Due to the persistence of global manufacturing and supply-chain disruptions and a few other hostile externalities, three stocks are likely to register a dull 2021 performance.

Other stocks mentioned: MDRX, PACB
Business Wire - 1 month ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces it has surpassed more than 1,000 patents worldwide, with more than 850 additional patents pending. Abiomed's robust intellectu...

Seeking Alpha - 1 month ago

Abiomed's AAA financials, including a clean balance sheet and world-class margins can justify a premium in its valuation. Discounting Abiomed's future free cash flows, we derive the stock's in...

Business Wire - 1 month ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 39th annual J.P. Morgan Healthcare conference.

Zacks Investment Research - 2 months ago

Abiomed (ABMD) successfully treats first two patients in the world with the help of its Breethe OXY-1 System.

Business Wire - 2 months ago

DANVERS, Mass.--(BUSINESS WIRE)--The first two patients in the world have been treated with the Abiomed Breethe OXY-1 System, including a COVID-19 patient in respiratory failure.

Business Wire - 2 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the achievement of two milestones in the development of small bore access for the Impella heart pump. The Impella ECP heart pu...

The Motley Fool - 3 months ago

Biotech stocks simply can't match these reliable returns.

Other stocks mentioned: DXCM, MDT
Business Wire - 3 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Stephens Annual Investment Conference 2020.

The Motley Fool - 3 months ago

It depends on whether or not the company's decelerating revenue growth is a symptom of larger problems.

Business Wire - 3 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces 1,000 patients have been treated with the Impella 5.5 with SmartAssist heart pump in the first year after the U.S. Food and Dr...

The Motley Fool - 3 months ago

Revenue bounces back, but growth is still lacking.

Seeking Alpha - 3 months ago

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

ABIOMED's (ABMD) international Impella revenues improved in Q2.

Zacks Investment Research - 3 months ago

Abiomed (ABMD) delivered earnings and revenue surprises of 16.09% and 4.16%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Business Wire - 3 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces Q2 FY 2021 revenue of $210 million, up 27% over Q1 FY 2021 and up 2% over Q2 FY 2020 with 29.2% operating margin.

Business Wire - 3 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest ...

Zacks Investment Research - 3 months ago

The full commercial launch of Impella 5.5 in May is expected to have contributed to ABIOMED's (ABMD) fiscal second-quarter results

Business Wire - 3 months ago

DANVERS, Mass.--(BUSINESS WIRE)--The U.S. FDA has granted Abiomed 510(k) clearance for an all-in-one, compact cardiopulmonary bypass system called the Abiomed Breethe OXY-1 Systemâ„¢.

Zacks Investment Research - 4 months ago

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes - 4 months ago

The stock price of Abiomed, a medical devices company best known for Impella, the world's smallest heart pump, is up roughly 60% since the beginning of this year, significantly outperforming t...

The Motley Fool - 4 months ago

New trial data supports the use of the company's Impella heart pumps in high-risk patients undergoing surgery to treat their coronary heart disease.

Business Wire - 4 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host a virtual meeting to discuss new clinical data presented at TCT Connect.

Business Wire - 4 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarction and rep...

Zacks Investment Research - 4 months ago

IART vs. ABMD: Which Stock Is the Better Value Option?

Other stocks mentioned: IART
The Motley Fool - 4 months ago

Look for proven resilience and growth prospects on the horizon.

Other stocks mentioned: EXEL, TDOC
The Motley Fool - 4 months ago

Abiomed is definitely not cheap, but there is significant upside left in this stock.

The Motley Fool - 4 months ago

This company's medical products can help patients suffering from COVID-19's most dangerous complications.

Business Wire - 4 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed will release financial results for the second quarter of fiscal 2021 on Thursday, October 29, 2020 at 8:00 a.m. ET.

GuruFocus - 4 months ago

Some countries, the U.S. in particular, are growing older - i.e. they have "aging populations.

Business Wire - 5 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the Raymond James North American Equities Conference.

Business Wire - 5 months ago

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to hold fireside chat at the 18th annual Morgan Stanley Global Healthcare Conference.

Zacks Investment Research - 5 months ago

Abiomed (ABMD) reported earnings 30 days ago. What's next for the stock?

The Motley Fool - 5 months ago

Some of the names on this list may surprise you.

Other stocks mentioned: DXCM, IDXX, REGN, WST

About ABMD

Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are p... [Read more...]

Industry
Medical Devices
IPO Date
Jul 29, 1987
CEO
Michael Minogue
Employees
1,536
Stock Exchange
NASDAQ
Ticker Symbol
ABMD
Full Company Profile

Financial Performance

In 2019, Abiomed's revenue was $840.88 million, an increase of 9.29% compared to the previous year's $769.43 million. Earnings were $203.01 million, a decrease of -21.62%.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for Abiomed stock is "Buy." The 12-month stock price forecast is 378.00, which is an increase of 18.51% from the latest price.

Price Target
$378.00
(18.51% upside)
Analyst Consensus: Buy